This trial is active, not recruiting.

Conditions chronic obstructive pulmonary disease (copd), emphysema, endothelial dysfunction
Sponsor Columbia University
Collaborator National Heart, Lung, and Blood Institute (NHLBI)
Start date October 2004
End date November 2012
Trial size 4359 participants
Trial identifier NCT00843271, AAAA7791, NCT00094224, R01HL077612


The purpose of MESA-Lung is to assess the role of endothelial dysfunction and genetic susceptibility in subclinical COPD.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
MESA-Lung is an ancillary study of the Multi-Ethnic Study of Atherosclerosis (MESA). MESA, established in 1999, is well characterized, multi-ethnic (white, Black, Hispanic and Chinese), and multi-center (Columbia, Johns Hopkins, Northwestern, UCLA, Minnesota,and Wake Forest) prospective cohort study. MESA-Lung included a 60% random sample of the MESA cohort at the six Field Centers in Exam 3 and Exam 4, stratified on race/ethnicity.

Primary Outcomes

Lung Function
time frame: 2004-2011

Secondary Outcomes

Lung Density
time frame: 2000-2011

Eligibility Criteria

Male or female participants from 45 years up to 84 years old.

Inclusion Criteria: - A random sample of MESA participants active at Exam 3 and/or 4. Exclusion Criteria: - MESA participants without MESA Exam 3 or 4 measurements. - MESA participants without FMD measurements in Exam 1. - MESA participants who have not consented to genetic testing.

Additional Information

Official title Endothelial Dysfunction, Biomarkers, and Lung Function (MESA LUNG)
Principal investigator R. Graham Barr, M.D., Dr.PH.
Description Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death in the United States, and morbidity and mortality from COPD continue to rise. Despite the magnitude of the problem, therapeutic options are limited - particularly in comparison to cardiovascular disease. Smoking cessation is essential to the treatment and prevention of COPD. However, although smoking is the principal cause of COPD, only a minority of smokers develops symptomatic COPD and many former smokers develop COPD years to decades after they have stopped smoking. The only other medical intervention proven to reduce mortality from COPD is supplemental oxygen therapy. There is therefore an urgent need for newer understandings of the pathophysiology of COPD that might lead to the development of better therapies for COPD. MESA-Lung is ancillary of the ongoing Multi-Ethnic Study of Atherosclerosis (MESA). MESA-lung will utilize the various existing measures of endothelial function that have been already been collected in MESA (flow-mediated dilatation [FMD] and related biomarkers and gene polymorphisms) to test the hypotheses that the endothelial dysfunction occurs in the clinical COPD.
Trial information was received from ClinicalTrials.gov and was last updated in January 2012.
Information provided to ClinicalTrials.gov by Columbia University.